Tiotropium Respimat® Versus HandiHaler®: Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Introduction

The long-acting muscarinic antagonist tiotropium bromide is approved in many countries as maintenance therapy for chronic obstructive pulmonary disease (COPD). Tiotropium is available as a dry-powder formulation delivered via HandiHaler ^® (18 μg once daily) and is now also approved as an aqueous solution delivered via the Respimat ^® Soft Mist™ Inhaler (5 μg once daily, 2 puffs of 2.5 µg). Several studies have compared the efficacy of tiotropium HandiHaler (18 μg once daily) with different doses of Respimat. We aimed to compare available bronchodilator efficacy data of once-daily Respimat 1.25, 2.5, 5, 10, 20 µg, and HandiHaler 18 µg to investigate which dose of tiotropium delivered by Respimat is the closest match to tiotropium HandiHaler.

Methods

Evaluation of six clinical trials (duration from 3 weeks to 2–3 years) that included lung function measures (trough forced expiratory volume in 1 s and trough forced vital capacity) as key outcomes.

Results

In the six trials, bronchodilator efficacy of Respimat 5 μg and HandiHaler 18 μg was similar; however, reduced bronchodilator efficacy was observed with lower doses of Respimat (1.25 and 2.5 μg).

Conclusion

These findings support the use of the marketed once-daily dose of Respimat 5 μg for the maintenance treatment of patients with COPD.

Funding

Boehringer Ingelheim.

Related collections

Most cited references 10

Record: found
Abstract: found
Article: not found

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Claus Vogelmeier, Bettina M Hederer, Thomas Glaab … (2011)

Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD. In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year. A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P<0.001). Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001), reduced the annual number of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P=0.002), and reduced the annual number of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P<0.001). Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups. There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group. These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.).

0 comments Cited 205 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Tiotropium Respimat inhaler and the risk of death in COPD.

Robert Wise, Antonio Anzueto, Daniel Cotton … (2013)

Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.

0 comments Cited 114 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.

E Bateman, L Towse, R Dahl … (2010)

In this randomised double-blind study, patients >or=40 years old with COPD, a smoking history of >or=10 pack-years, a pre-bronchodilator FEV(1) of

0 comments Cited 48 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Peter M. A. Calverley: pmacal@liverpool.ac.uk

Journal

Journal ID (nlm-ta): Adv Ther

Journal ID (iso-abbrev): Adv Ther

Title: Advances in Therapy

Publisher: Springer Healthcare (Cheshire )

ISSN (Print): 0741-238X

ISSN (Electronic): 1865-8652

Publication date (Electronic): 28 March 2016

Publication date PMC-release: 28 March 2016

Publication date (Print): 2016

Volume: 33

Pages: 786-793

Affiliations

[ ]Pulmonary and Rehabilitation Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK

[ ]Clinical Development + Medical Affairs, Boehringer Ingelheim, Ingelheim, Germany

[ ]Medicine TA Respiratory Diseases, Boehringer Ingelheim, Ingelheim, Germany

[ ]Statistics, Boehringer Ingelheim, Bracknell, UK

[ ]Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany

Article

Publisher ID: 322

DOI: 10.1007/s12325-016-0322-9

PMC ID: 4882367

PubMed ID: 27084728

SO-VID: e0e37126-f3a4-4d60-bd43-950203322b50

History

Date received : 25 January 2016

Funding

Funded by: FundRef http://dx.doi.org/10.13039/100008349, Boehringer Ingelheim;

Custom metadata

Keywords: bronchodilator,chronic obstructive pulmonary disease (copd),dose–response,efficacy,long-acting muscarinic antagonist,lung function,once-daily,pulmonology,respimat®,spirometry,tiotropium

Data availability:

Keywords: bronchodilator, chronic obstructive pulmonary disease (copd), dose–response, efficacy, long-acting muscarinic antagonist, lung function, once-daily, pulmonology, respimat®, spirometry, tiotropium

Comments

Comment on this article

scite_

Cited by 1

The Respimat® Development Story: Patient-Centered Innovation
Authors: Herbert Wachtel, Sabine Kattenbeck, Stephen Dunne …

See all cited by

Most referenced authors 349

See all reference authors